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Heart transplantation has been extremely successful as a field,
but continues to be plagued by a small number of severe
complications. Among these, one of the most frustrating
may be cardiac allograft vasculopathy (CAV), a concentric
non-atherosclerotic intimal thickening leading to narrowing of
the cardiac arterial vasculature and progressive ischemia in
allografts [1]. A similar phenomenon is seen in all
transplanted organs, and seems to be an immunologically
mediated event, despite limited to no response to current
immunosuppressive therapies. This CAV phenomenon is
one of the most limiting factors in the survival of an individual
with a cardiac allograft, and is a common cause of ischemic
disease leading to graft failure and retransplantation or death.
CAV can involve epicardial coronary arteries, thus clinically
mimicking atherosclerotic disease, as well as intramyocardial
arteries of any size. Coronary angiography performed on
transplant patients is effective at monitoring the epicardial
disease, and biopsy features may suggest ischemic damage,
but there are no good tools yet for formally monitoring the
small vessel narrowing (although surrogate measures of per-
fusion do exist) [2,3]. Likewise, while stents and bypass are
available on a selected basis for the epicardial vessels, no such
therapies exist for the small vessel pathology [4–6].
Improved prevention and treatment of CAV will re-
quire improved understanding of the pathophysiology of
the entity itself. One particularly promising advance in
this research is presented in this issue by Wang and
colleagues [7]. Using a mouse model, they present com-
pelling evidence that suggests memory T cells may be
intimately involved in the development of CAV, and
specifically suggest that blockade of the TNF receptor
family member OX40 (CD134) may be a therapeutic
target in this context. Their model utilizes homeostatic
proliferation (Fig. 1), the expansion of lymphocyte pop-
ulations in a lymphocyte-poor environment [8,9]. Al-
though their model uses lymphocyte deficient mice re-
ceiving a T-cell transfer from syngeneic donors, the
authors point out the parallels between this situation
and the immune reconstitution that occurs in a heart
transplant recipient following induction therapies. As
laid out by the authors, memory T cells may be much
more difficult to eradicate prior to transplantation, and
may thus be prone to rapid response on exposure to the
allograft. By identifying a candidate tool for targeting
these cells, i.e. OX40 blockade, these authors suggest a
strategy for potentially stopping CAV before it even
begins.
Further, the authors’ work adds to a small number of
murine models of CAV, each with slightly different reflections
of the potential pathophysiology at work in humans [1]. These
models have allowed a number of candidate immunologic
therapies for CAV to emerge, including the OX40 blockade
suggested in this study. The tools to evaluate human tissues
and blood for evidence of analogous mechanisms exist, and
thus it is possible to generate the required preliminary data to
initiate human investigations. Biologic therapy, i.e. use of
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monoclonal antibodies and/or recombinant proteins to inhibit
biologic pathways in vivo, has become a major tool in oncol-
ogy, rheumatology, neurology, gastroenterology, and trans-
plantation [10,11]. These highly targeted therapies present
powerful opportunities to intervene in processes in patients,
but much more study is required. Besides just documenting
that the pathways identified in mice are also at work in human,
there are a large number of potential complications and side
effects that need to be explored, such as excessive immuno-
suppression leading to opportunistic infection.
Huge advances in immunology continue to informmedical
practice, in particular the transplantation field. Ongoing appli-
cation of that knowledge will lead to improved outcomes,
although much work is required.
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Fig. 1 Homeostatic proliferation. a In the normal lab mouse or the pre-
transplant human, there is a mixed population of T cells in the circulation
and tissue, with memory Tcells (green) representing a relative minority of
the population. b In immunodeficient mice that have just received adop-
tive transfer of T cells, or in a transplant patient that has undergone
induction of immunosuppression, only a small population of T cells
remains, although memory T cells will represent a larger fraction of these
cells. cHomeostatic proliferation (HP) is the process by which this small
number of T cells (panel b) proliferates to restore an approximately
normal number of T cells in the circulation and tissue; in this situation,
memory T cells remain a larger fraction of the overall population
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